ibuprofen has been researched along with Urinary Bladder, Overactive in 2 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Urinary Bladder, Overactive: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, KC | 1 |
| Rauscher, F | 1 |
| Kaminesky, J | 1 |
| Ryndin, I | 1 |
| Xie, L | 1 |
| Zhao, Y | 1 |
| Khusid, JA | 1 |
| Weiss, JP | 1 |
| Wein, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Paxerol™ (a Novel Formulation of Acetaminophen and Ibuprofen) for Treatment of Nocturia - A Phase II Placebo-Controlled Trial[NCT02646826] | Phase 2 | 86 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in number of nocturia episodes associated with one of three dose levels of Paxerol vs. placebo is assessed during the 2-week treatment period. (NCT02646826)
Timeframe: Up to 2 weeks
| Intervention | average nightly voids (Mean) | ||
|---|---|---|---|
| Baseline | Two Weeks Using Pills | Change of Nocturia Episodes | |
| Paxerol - Dose Level 1 325 mg Acetaminophen 150 mg Ibuprofen | 3.3 | 2.2 | -1.1 |
| Paxerol - Dose Level 2 650 mg Acetaminophen 300 mg Ibuprofen | 3.9 | 2.5 | -1.4 |
| Paxerol - Dose Level 3 975 mg Acetaminophen 450 mg Ibuprofen | 3.6 | 2.4 | -1.3 |
| Placebo | 3.6 | 3.2 | -0.3 |
The degree of clinical benefit, via NQOL, associated with one of three dose levels of Paxerol vs. placebo is assessed after the 2-week treatment period. This is on a scale of 0 to 100, with 0 being the best score. (NCT02646826)
Timeframe: Up to 2 weeks
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline Quality of Life | Two Weeks Using Pills | |
| Paxerol - Dose Level 1 325 mg Acetaminophen 150 mg Ibuprofen | 52.3 | 40.7 |
| Paxerol - Dose Level 2 650 mg Acetaminophen 300 mg Ibuprofen | 63.6 | 40.5 |
| Paxerol - Dose Level 3 975 mg Acetaminophen 450 mg Ibuprofen | 59.7 | 37.4 |
| Placebo | 52.5 | 42.1 |
DFUS will be assessed during the 2-week treatment period with one of three dose levels of Paxerol vs. placebo (NCT02646826)
Timeframe: Up to 2 weeks
| Intervention | Hours (Mean) | |
|---|---|---|
| Baseline DFUS | Two Weeks Using Pills DFUS | |
| Paxerol - Dose Level 1 325 mg Acetaminophen 150 mg Ibuprofen | 2.2 | 2.8 |
| Paxerol - Dose Level 2 650 mg Acetaminophen 300 mg Ibuprofen | 2.0 | 2.7 |
| Paxerol - Dose Level 3 975 mg Acetaminophen 450 mg Ibuprofen | 2.1 | 3.3 |
| Placebo | 1.8 | 2.2 |
The total hours of nightly sleep will be assessed during the 2-week treatment period with one of three dose levels of Paxerol vs. placebo (NCT02646826)
Timeframe: Up to 2 weeks
| Intervention | Hours per night (Mean) | ||
|---|---|---|---|
| Baseline Hours of Sleep | Two Weeks Using Pills Hours of Sleep | Change from Baseline | |
| Paxerol - Dose Level 1 325 mg Acetaminophen 150 mg Ibuprofen | 7.9 | 7.7 | -0.3 |
| Paxerol - Dose Level 2 650 mg Acetaminophen 300 mg Ibuprofen | 8.6 | 8.5 | -0.2 |
| Paxerol - Dose Level 3 975 mg Acetaminophen 450 mg Ibuprofen | 8.6 | 8.4 | -0.2 |
| Placebo | 8.5 | 8.3 | -0.3 |
1 trial available for ibuprofen and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi-center, randomized, double blinded, placebo-controlled, 4-arm trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Method; Dru | 2019 |
1 other study available for ibuprofen and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial.
Topics: Acetaminophen; Delayed-Action Preparations; Double-Blind Method; Humans; Ibuprofen; Nocturia; Urinar | 2019 |